Graft-versus-Host Disease (Hepatic)

What is Graft-versus-Host Disease (Hepatic)?

Hepatic graft-versus-host disease is a condition that affects the liver after a stem cell or bone marrow transplant. It happens when donor immune cells attack your bile ducts, the small tubes that carry bile from your liver to your intestines. This attack causes inflammation and blocks the normal flow of bile.

The condition can develop weeks to months after transplant. When bile cannot flow properly, it builds up in your liver and bloodstream. This buildup, called cholestasis, causes bilirubin levels to rise. Bilirubin is a yellow substance that forms when your body breaks down old red blood cells.

Hepatic GVHD requires careful monitoring and treatment to protect your liver function. Early detection through blood testing helps your medical team adjust your medications before serious liver damage occurs. Most people with this condition need changes to their immunosuppression therapy to calm the donor immune response.

Bilirubin, Total

Reveal liver health issues effortlessly
Clarify the cause of jaundice symptoms
Detect bile duct problems early

^$31

Comprehensive Metabolic Profile (includes eGFR)

Reveal underlying health conditions effortlessly
Pinpoint the cause of chronic fatigue
Assess your cardiovascular health comprehensively

^$39

Liver Function Profile

Reveal liver issues before they become serious
Clarify why you're feeling constantly tired
Expose hidden factors affecting your digestion

^$46

Symptoms

Many people with hepatic GVHD notice symptoms as bilirubin levels rise:

Yellowing of the skin and eyes, called jaundice
Dark urine that looks brown or tea-colored
Pale or clay-colored stools
Itching all over the body, especially at night
Pain or discomfort in the upper right abdomen
Nausea or loss of appetite
Fatigue and weakness
Unexplained weight loss

Some people have no symptoms in the early stages. Blood tests often detect rising bilirubin before you feel unwell. This is why regular monitoring after transplant is so important.

Causes and risk factors

Hepatic GVHD occurs when donor immune cells from your transplant recognize your bile ducts as foreign tissue. These cells attack the small bile ducts in your liver, causing inflammation and damage. The exact reason some people develop this complication while others do not is not fully understood. Your immune system compatibility with your donor plays a major role.

Risk factors include receiving a transplant from an unrelated or partially matched donor, having acute GVHD in other organs first, and being older at the time of transplant. The type of transplant preparation you received and the immunosuppression regimen also affect your risk. Most cases develop between 30 and 100 days after transplant, though chronic forms can appear later.

How it's diagnosed

Doctors diagnose hepatic GVHD primarily through blood tests that measure bilirubin levels. Total bilirubin rises when bile ducts are damaged and bile cannot flow normally. Your transplant team will check your bilirubin regularly after your procedure. Rising levels alert them to possible hepatic GVHD before serious damage occurs.

Rite Aid offers convenient bilirubin testing through our flagship panel at Quest Diagnostics locations nationwide. Additional tests may include liver enzymes and imaging studies. In some cases, a liver biopsy confirms the diagnosis. Your transplant specialist will review all results to determine if your immunosuppression therapy needs adjustment.

Treatment options

Treatment focuses on reducing the immune attack on your bile ducts while protecting liver function:

Adjusting immunosuppression medications to calm donor immune cells
Adding corticosteroids like prednisone to reduce inflammation
Using ursodeoxycholic acid to improve bile flow and protect bile ducts
Managing itching with antihistamines or bile acid sequestrants
Maintaining good nutrition with vitamin supplements, especially fat-soluble vitamins
Avoiding alcohol and medications that stress the liver
Monitoring bilirubin and liver function regularly through blood tests
Working closely with your transplant team to catch changes early

Most people respond to medication adjustments within weeks to months. Some cases become chronic and require long-term management. Your transplant specialist will guide your treatment based on your bilirubin levels and overall health.

Frequently asked questions

Acute hepatic GVHD typically develops within the first 100 days after transplant and causes rapid rises in bilirubin. Chronic hepatic GVHD appears later, often after 100 days, and may develop more gradually. Both forms damage bile ducts but may require different treatment approaches. Your transplant team monitors timing and symptoms to determine which type you have.

Most transplant centers check bilirubin weekly for the first few months after transplant. Testing frequency decreases as you recover and your risk drops. If you develop symptoms or your doctor suspects hepatic GVHD, you may need testing several times per week. Your transplant team will create a monitoring schedule based on your individual risk factors.

Preventive immunosuppression after transplant reduces the risk of all forms of GVHD, including hepatic. Most patients receive medications like tacrolimus or cyclosporine starting before transplant. Some centers use ursodeoxycholic acid to protect bile ducts during the high-risk period. While these strategies help, they cannot eliminate the risk entirely.

Normal total bilirubin is usually below 1.2 mg/dL. Hepatic GVHD is suspected when bilirubin rises above 2 mg/dL, especially if it increases rapidly. The specific threshold varies by transplant center and individual baseline levels. Your transplant team considers the pattern of change, not just a single number.

Many cases improve with prompt treatment and medication adjustments. Mild to moderate hepatic GVHD often resolves completely with increased immunosuppression. Severe cases or those with delayed treatment may cause permanent bile duct damage. Early detection through regular bilirubin testing gives you the best chance of full recovery.

Yes, hepatic GVHD can occur alone, though it often appears alongside skin or gut involvement. Some people develop isolated liver GVHD as their only transplant complication. Others experience hepatic GVHD as part of widespread disease affecting multiple organs. Your transplant team monitors all potential target organs, not just the liver.

Itching happens when bile acids build up in your bloodstream due to blocked bile flow. These substances deposit in your skin and trigger intense itching, especially at night. The itching often appears before jaundice becomes visible. Medications that bind bile acids or improve bile flow can help reduce this uncomfortable symptom.

Not always. Many cases are diagnosed based on rising bilirubin levels, timing after transplant, and response to treatment. Your doctor may recommend biopsy if the diagnosis is unclear or other liver problems need to be ruled out. Biopsy shows characteristic damage to small bile ducts. Your transplant team decides if biopsy is necessary in your situation.

Good nutrition supports liver health, though diet alone cannot treat hepatic GVHD. Focus on adequate calories and protein to maintain strength during treatment. You may need supplements of vitamins A, D, E, and K, which require bile for absorption. Avoid alcohol completely, as it stresses your already compromised liver.

Most cases improve with medication adjustments, but some prove resistant to standard therapy. Your transplant team may try additional immunosuppression drugs or newer treatments. Severe, untreated hepatic GVHD can lead to liver failure requiring intensive support. This is rare with modern monitoring and treatment approaches.